Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.
The Company offers OGM solutions for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
Optical genome mapping (OGM) is a workflow that combines various technologies for one purpose: to reveal structural variation in a way that’s never been done before.
OGM begins with the isolation of ultra-high molecular weight (UHMW) DNA from blood, bone marrow aspirates, cultured cells (including chorionic villi and amniocytes), tissue, or tumor biopsies. A single enzymatic reaction places fluorescent labels all throughout the genome at a specific sequence motif. The labeled DNA molecules are linearized in nanochannel arrays on the chip. Changes in the patterning or spacing of the labels are identified by software solutions to accurately detect all classes of structural variants (SVs). The OGM data generated can be analyzed alone, or in combination with sequencing or array data.